Prime Medicine, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 9.92K shares.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 101.50K shares.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 115.03K shares, a 1200.54% increase year-over-year.
- Prime Medicine, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 9.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | 101.50K shares 10-Q · filed 2026-05-07 | |
| 2025-09-30 | 115.03K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | |
| 2024-09-30 | 8.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2024-06-30 | 9.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | |
| 2024-03-31 | 9.66K shares 10-Q · filed 2024-05-10 | |
| 2023-09-30 | 54.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | |
| 2023-06-30 | 42.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | |
| 2023-03-31 | 18.60K shares 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |